Cargando…

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study

Laquinimod is a novel orally administered drug for the treatment of relapsing remitting multiple sclerosis (RRMS). In this immunological substudy of the phase III Assessment of Oral Laquinimod in Preventing Progression of MS (ALLEGRO) trial, we performed an ex vivo and in vitro analysis of effects e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stasiolek, Mariusz, Linker, Ralf A, Hayardeny, Liat, Bar Ilan, Oren, Gold, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444148/ https://www.ncbi.nlm.nih.gov/pubmed/26029365 http://dx.doi.org/10.1002/iid3.42

Ejemplares similares

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
por: Lee, De-Hyung, et al.
Publicado: (2012)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inflammation in multiple sclerosis
por: Haase, Stefanie, et al.
Publicado: (2021)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Navigating choice in multiple sclerosis management
por: Linker, Ralf A., et al.
Publicado: (2019)

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2023)

Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
por: Mandrioli, Jessica, et al.
Publicado: (2023)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?
por: Oset, Magdalena, et al.
Publicado: (2020)

Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial
por: Sung, Valerie, et al.
Publicado: (2014)

Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial
por: Riche, Daniel M., et al.
Publicado: (2014)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

The Effect of Oral Vitamin E on Semen Parameters and IVF Outcome: A Double-Blinded Randomized Placebo-Controlled Clinical Trial
por: Sabetian, Soudabeh, et al.
Publicado: (2021)

Monitoring oral propranolol for infantile hemangiomata
por: Bar, Jonathan, et al.
Publicado: (2022)

Use of pethidine for percutaneous liver biopsy – a randomised, placebo-controlled, double blind study
por: Pan, Antony, et al.
Publicado: (2015)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
por: Walter, Maggie C, et al.
Publicado: (2013)

Effect of the Oral Intake of Astaxanthin on Semen Parameters in Patients with Oligo-astheno-teratozoospermia: A Randomized Double-blind Placebo-controlled Trial
por: Kumalic, Senka Imamovic, et al.
Publicado: (2020)

Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
por: Grube, Barbara, et al.
Publicado: (2015)

Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage
por: Linker, Ralf A., et al.
Publicado: (2009)

Oral lactase for infantile colic: a randomized double-blind placebo-controlled trial
por: Narang, Manish, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fob4qrtvm5sn0sjajav8r8nois